d) response to intervention
The response to intervention by modulator therapy was assessed by
evaluating the change in LCI between baseline, i.e. before treatment
start and after at least two weeks of treatment in three different
treatment groups: In (i) either Orkambi® (Lumacaftor/Ivacaftor) or
Symdeko® (Tezacaftor/Ivacaftor)-treated patients (double modulator
therapy), in (ii) Trikafta® (Elexacaftor/Tezacaftor/Ivacaftor)–treated
patients (triple modulator therapy), and (iii) patients who received
first Orkambi® or Symdeko® followed by Trikafta® (combined modulator
therapy). Response to intervention was defined as within-group changes
from baseline to under treatment and analyzed by paired t-tests.
Results
3.1 Study
population
Summaries for demographical characteristics and number of measurements
included are presented in Table 1.